Printer Friendly

Vanda signs license agreement for CFTR activators and inhibitors with UCSF.

M2 PHARMA-March 30, 2017-Vanda signs license agreement for CFTR activators and inhibitors with UCSF

(C)2017 M2 COMMUNICATIONS

Biopharmaceutical company Vanda Pharmaceuticals Inc (NasdaqGM:VNDA) reported on Wednesday the launch of an agreement to acquire an exclusive worldwide license to develop and commercialise a portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors from UC San Francisco (UCSF).

As part of the agreement, Vanda will pay UCSF an initial license fee of USD1m plus responsible for all development costs. UCSF is eligible to receive up to USD46m in potential development, regulatory and sales milestones as well as single-digit tiered royalties on net sales should a product be successfully commercialised.

Vanda stated that CFTR activators and inhibitors may have broad applicability in addressing a number of high unmet medical needs, including chronic dry eye, constipation, polycystic kidney disease, cholestasis and secretory diarrhea.

The CFTR activators and inhibitors was developed in the UCSF laboratory of Alan S. Verkman, MD, PhD. The portfolio of compounds are at a pre-investigational new drug (IND) stage, and in addition to ongoing chemistry optimization work, several lead compounds have been identified for further IND-enabling work.

In 2017, Vanda plans to complete the technology transfer activities from UCSF and initiate IND enabling studies for several CFTR indications.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 30, 2017
Words:222
Previous Article:Tonix Pharmaceuticals plans to issue common stock in public offering.
Next Article:Roche's OCREVUS (ocrelizumab) gains US FDA approval for relapsing and primary progressive forms of multiple sclerosis.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters